Indiana Consortium For Mental Health
Services Research

Indiana University, Bloomington, Indiana

Home Contacts Faculty Publications Core Projects Intensive Weekend Workshops Newsletters  

   

Search:

 

Abstract

Reprint # 54: Determinants of Antidepressant Treatment Compliance: Implications for Policy

Ming Tai-Seale Indiana University,
Thomas W. Croghan, Eli Lilly and Company and Indiana University,
Robert Obenchain, Eli Lilly and Company

Depression is among the most prevalent, devastating, and undertreated disorders in our society. Treatment with antidepressant medications is effective in controlling symptom, but treatment beyond the point of symptom resolution is necessary to restore functional status and prevent recurrent episodes. An important step in improving compliance is to identify the determinants of antidepressant treatment compliance. A broader motivation for our study is to examine compliance by patients with a chronic but treatable disease. With claims data between 1990 and 1993, this study uses logistic regression analysis to examine the determinants of compliance among 2,012 antidepressant recipients. The results show that initiating treatment with a tricyclic antidepressant reduces the probability of antidepressant treatment compliance. Initiating treatment with a selective serotonin reuptake inhibitor and undergoing family, group, or individual psychotherapy treatments increase the probability of compliance. Case management does not meaningfully affect compliance. Implications for policy and clinical practice are discussed.

 

 

1022 E. Third Street, Bloomington, IN 47405 Tel: (812) 855-3841 Fax: (812)856-5713

Indiana University

Last updated: 15 September 2004
Comments: icmhsr@indiana.edu
Copyright 2004, The Trustees of Indiana University
Copyright Complaints